Tuberculous fibrosis of lung

Summary

Tuberculous fibrosis of lung (MONDO:0021953) is a disease. A subtype of pulmonary fibrosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tuberculous fibrosis of lung
Mondo ID	MONDO:0021953
NCIT	C35088
SNOMED CT	90117007
UMLS	C0041336
MedGen	21729
GARD	0025358
Is cancer (heuristic)	no

Also known as: tuberculous fibrosis of lung

Disease family

This is a subtype of pulmonary fibrosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › pulmonary fibrosis › tuberculous fibrosis of lung

Related subtypes (5): pulmonary fibrosis and/or bone marrow failure, telomere-related, postinflammatory pulmonary fibrosis, diffuse pulmonary fibrosis, localized pulmonary fibrosis, graphite pneumoconiosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.